Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study

James Wilton,1 Younathan Abdia,1,2 Mei Chong,1 Mohammad Ehsanul Karim,2,3 Stanley Wong,1 Aaron MacInnes,4,5 Rob Balshaw,6 Bin Zhao,1 Tara Gomes,7,8 Amanda Yu,1 Maria Alvarez,1 Richard C Dart,10,11 Mel Krajen,1,12 Jane A Buxton,1,2 Naveed Z Janjua,1,2 Roy Purssell1,13

ABSTRACT
OBJECTIVE
To assess the association between long term prescription opioid treatment medically dispensed for non-cancer pain and the initiation of injection drug use (IDU) among individuals without a history of substance use.

DESIGN
Retrospective cohort study.

SETTING
Large administrative data source (containing information for about 1.7 million individuals tested for hepatitis C virus or HIV in British Columbia, Canada) with linkage to administrative health databases, including dispensations from community pharmacies.

PARTICIPANTS
Individuals age 11-65 years and without a history of substance use (except alcohol) at baseline.

MAIN OUTCOME MEASURES
Episodes of prescription opioid use for non-cancer pain were identified based on drugs dispensed between 2000 and 2015. Episodes were classified by the increasing length and intensity of opioid use (acute (lasting <90 episode days), episodic (lasting ≥90 episode days; with ≥90 days' drug supply and/or ≥50% episode intensity), and chronic (lasting ≥90 episode days; with ≥90 days' drug supply and ≥50% episode intensity)). Participants with a chronic episode were matched 1:1:1:1 on socioeconomic variables to those with episodic or acute episodes and to those who were opioid naive. IDU initiation was identified by a validated administrative algorithm with high specificity. Cox models weighted by inverse probability of treatment weights assessed the association between opioid use category (chronic, episodic, acute, opioid naive) and IDU initiation.

RESULTS
59804 participants (14,951 people from each opioid use category) were included in the matched cohort, and followed for a median of 5.8 years. 1149 participants initiated IDU. Cumulative probability of IDU initiation at five years was highest for participants with chronic opioid use (4.0%), followed by those with episodic use (1.3%) and acute use (0.7%), and those who were opioid naive (0.4%). In the inverse probability of treatment weighted Cox model, risk of IDU initiation was 8.4 times higher for those with chronic opioid use versus those who were opioid naive (95% confidence interval 6.4 to 10.9). In a sensitivity analysis limited to individuals with a history of chronic pain, cumulative risk for those with chronic use (3.4% within five years) was lower than the primary results, but the relative risk was not (hazard ratio 9.7 (95% confidence interval 6.5 to 14.5)). IDU initiation was more frequent at higher opioid doses and younger ages.

CONCLUSIONS
The rate of IDU initiation among individuals who received chronic prescription opioid treatment for non-cancer pain was infrequent overall (3.4% within five years) but about eight times higher than among opioid naive individuals. These findings could have implications for strategies to prevent IDU initiation, but should not be used as a reason to support involuntary tapering or discontinuation of long term prescription opioid treatment.

WHAT IS ALREADY KNOWN ON THIS TOPIC
Several qualitative and observational quantitative studies have assessed the association between prescription opioids and initiation of illicit drug use or injection drug use

Few large longitudinal studies exist, and most studies have instead examined self-reported non-medical prescription opioid use and initiation of heroin use

Non-medical use most commonly involves diverted prescription opioids obtained from sources other than a doctor (eg, friends, family, drug dealers); therefore, less is known about medically dispensed opioid treatment for pain

WHAT THIS STUDY ADDS
In this large longitudinal study of nearly 60,000 individuals, objective measures were used for both prescription opioid use and initiation of injection drug use (as opposed to relying on self-report), and medically dispensed opioid treatment for non-cancer pain (as opposed to non-medical use) was assessed

Although the overall rate of injection drug use initiation among individuals with chronic use of prescription opioids was infrequent (3.4% within five years), the rate was 8-10 times higher than for opioid naive individuals

Introduction
Injection drug use is associated with substantial morbidity and mortality,1 and the prevalence of this practice is increasing in some jurisdictions.2 3 Harms associated with injection drug use include HIV, hepatitis C virus, infective endocarditis, skin and soft tissue infections, and overdose.4 5 In Canada, the estimated number of people who inject drugs increased from 130 000 to 171 900 between 2011 and 2016.6 In the US, an estimated one million people reported injection drug use in the past 12 months.6 Identification of populations at higher risk of initiating injection drug use is critical to prevent transitions to this practice and reduce secondary harms.7

Medical use of opioids to treat acute and chronic pain is widespread in North America.8 9 In general,
prescription opioids are not recommended as first line treatment of chronic non-cancer pain due to limited long term benefit and risk of harms, but adequate non-opioid alternatives are often unavailable or inaccessible (eg, owing to limited insurance coverage, poor availability of multidisciplinary pain clinics, or long wait times for pain management specialists). Large increases in opioid prescribing in North America began in the late 1990s—driven in part by aggressive marketing and a heightened focus on pain management—and were followed by increases in opioid overdose deaths. A systematic review of prescription opioid treatment for chronic pain estimated average rates of opioid misuse and addiction to be 21-29% and 8-12%, respectively.

People prescribed opioids for pain could be at higher risk of initiating illicit or injection drug use. Individuals on long term opioid treatment tend to have a higher prevalence of potential risk factors for illicit or injection drug use, including chronic pain, lower socioeconomic status, mental health issues, and substance use. Further, qualitative studies suggest that prescription opioids can facilitate initiation of heroin or injection drug use, and these transitions can be motivated by increasing tolerance, relief of pain or withdrawal, desire for a better high, or sudden reduced access to opioid drug treatments. Recent initiatives to promote appropriate prescription opioid use have raised concerns related to involuntary tapering or discontinuation and subsequent transitions to the illicit drug market to manage pain or withdrawal. These concerns are supported by longitudinal studies identifying a heightened risk of harms after discontinuation of opioid treatment.

Little is known about the initiation of injection drug use among individuals medically prescribed opioids to manage pain. Instead, most quantitative research has focused on self-reported, so-called non-medical, prescription opioid use—which most often entails diverted prescription opioids obtained from friends, family members, or drug dealers—and its link to initiation of heroin use. While self-report is also used to measure the initiation of heroin and injection drug use in these studies, interest in the use of administrative data to identify injection drug use is increasing, because of the wide breadth of these databases and limitations with self-report. Overall, most administrative studies conducted so far have aimed to quantify prevalence of injection drug use in various jurisdictions (rather than initiation in specific populations, such people who are prescribed opioids for pain). Assessing initiation is important in order to establish temporality and identify potentially causal risk factors for transitioning to this practice. Identification of injection drug use in administrative data is challenged by the lack of specific diagnostic codes for injection, but validated algorithms exist with varying sensitivity and specificity.

In this paper, we used a large administrative data source (of about 1.7 million people) with broad capture of the population in British Columbia, Canada (about a third of the province’s population; all individuals tested for HIV or hepatitis C virus, to examine the association between prescription opioid treatment for non-cancer pain and subsequent initiation of injection drug use among individuals without a history of substance use at baseline.

Methods
Data sources
We used the Integrated Data and Evaluative Analytics (IDEAs) cohort (also known as the British Columbia Hepatitis Testers Cohort) to conduct our retrospective cohort study. The databases integrated within IDEAs and their linkage have been described previously (supplementary table A). The IDEAs cohort is composed of all individuals tested for hepatitis C virus or HIV at the British Columbia Centre for Disease Control Public Health Laboratory between 1992 and 2015, as well as reported cases of hepatitis B and tuberculosis. The laboratory conducts more than 95% of hepatitis C virus or HIV diagnostic testing in the province. These data are linked to data on medical visits (1990-2015), hospital admissions (1985-2015), emergency department visits (2012-15), cancer diagnoses (1923-2015), deaths (1985-2015), and pharmacy dispensations (1996-2015).

In British Columbia, HIV or hepatitis C virus testing is broadly offered to certain populations (eg, pregnant people, baby boomers, sexually active individuals). The IDEAs cohort is estimated to capture about a third of the province’s population and 40-50% of prescription opioid use in the province. Importantly, the IDEAs platform captures historical data on all participants, including data before and after an individual met the inclusion criteria (eg, before and after HIV or hepatitis C virus testing).

Long term prescription opioid treatment
Data on opioid medication dispensations were obtained from PharmaNet, a province wide database capturing dispensations from all community pharmacies in British Columbia (1996 onwards), regardless of payer. We identified all episodes of prescription opioid use for non-cancer pain between 1996 and 2015. As defined by others, an episode starts with an incident opioid prescription (defined as no drug supply available in the past six months) and ends once there has been another six months with no drug supply. When creating these episodes, we did not consider low dose codeine formulations (<30 mg per tablet), opioid formulations primarily used for cough suppression or opioid agonist treatment, injectable opioid formulations, or opioid dispensations occurring after a cancer or palliative care record.
of episode days covered by drug supply). Episodic episodes contained fewer than 90 days' drug supply and/or less than 50% of episode intensity, and chronic episodes contained at least 90 days' drug supply and at least 50% episode intensity. We have extensively characterised these definitions in a previous analysis.

Initiation of injection drug use
Participants were considered to have initiated injection drug use when the following two criteria occurred within one year of each other:

- Evidence of a problem related to the use of potentially injectable drugs (eg, diagnostic codes for dependence to opioids, cocaine, amphetamines, or benzodiazepines; prescription of opioid agonist treatment; supplementary table B); and
- Diagnosis of a possible injection related infection (eg, endocarditis, bacteraemia or sepsis, skin or soft tissue infections; supplementary table B).

In a validation study using the IDEas cohort and linked surveillance data with self-reported injection drug use, this algorithm had a sensitivity of 63% and specificity of 90% for identifying people who inject drugs. Despite the availability of alternative algorithms with a better balance between sensitivity and specificity, we opted for a highly specific algorithm that included a requirement for an injection related infection, because drug related diagnostic codes do not specify the route of drug administration (eg, injection or oral) and—given our study population—these codes could be flagging dependence to prescription opioids taken orally.

Study design (matched cohort)
We created a matched cohort to examine the association between long term prescription opioid treatment and initiation of injection drug use. Each matched grouping included one person with a chronic episode of opioid use, one person with episodic opioid use, one person with acute opioid use, and an opioid naive person—all who entered the analysis in the same year and at about the same age (within a difference of 1 year of age). In this article, we refer to these categories within each matched group as the prescription opioid use categories (chronic, episodic, acute, opioid naive).

To create the matched cohort, individuals with long term opioid use were classified into two groups, according to whether their first long term episode between 2000 and 2015 was episodic or chronic. Individuals with chronic opioid use were matched 1:1 to those with episodic opioid use, based on sociodemographic variables (birth year, sex, ethnic origin) and year of index date. Index date was defined as the initiation date of long term use (that is, start date of the first long term episode plus 90 days).

We next matched individuals with chronic opioid use (based on birth year, sex, and ethnic origin) to two groups of individuals without a history of long term prescription opioid use at baseline (1:1:1 to opioid naive and acute use individuals). These two groups of individuals without long term prescription opioid use were assigned the index date (baseline) of the person with chronic opioid use to whom they were matched. The two groups were defined on the basis of prescription opioid use before their index date (that is, no history of opioid use for opioid naive, and ≥1 acute episode for acute use).

Eligibility criteria (matched cohort)
We applied several inclusion and exclusion criteria before and during the matching process. We included individuals aged between 11 and 65 years at the index date (the injection drug use algorithm was only validated for this age range) and who had a record of living in British Columbia at least five years before index date.

We excluded individuals who had a cancer or palliative care diagnosis or evidence of substance use problems before index date. We were conservative with regards to the second exclusion criteria, and excluded all individuals meeting a more sensitive version of our injection drug use algorithm (sensitivity 91%, specificity 72%; supplementary table B). This algorithm excluded the injection related infection requirement and captured a broader range of substance use diagnostic codes (but did not include alcohol). To further improve sensitivity, we also excluded individuals who were living with HIV or had been given a diagnosis of hepatitis C virus.

Before matching, we also excluded individuals who had missing sex or high level geographical information (health authority). However, we included individuals who were missing social or material deprivation information, because the lack of geographical information could be a proxy for homelessness.

Statistical analysis
Participants were followed from the index date to the earliest of the following: injection drug use initiation, 66 years of age, out-migration (two years after the last record in linked databases), initiation of a long term prescription opioid episode (only applicable to individuals in the acute use and opioid naive categories), study end (end of 2015 or 10 years of follow-up), or death. Individuals in the opioid naive and episodic use categories were not censored at initiation of an acute or chronic episode, respectively.

We used cumulative incidence curves to measure the cumulative probability of injection drug use initiation and Cox models to quantify the relative association between opioid use category (chronic, episodic, acute, opioid naive) and injection drug use initiation. In subanalyses, we stratified individuals with chronic opioid use by average daily dose across their first chronic episode. Average daily dose was calculated as the cumulative morphine equivalents prescribed during the episode divided by number of episode days covered by drug supply.

We weighted Cox models by inverse probability of treatment weights (IPTW). The generalised propensity
scores used to derive IPTW were calculated from a multinomial logistic regression model with opioid use category as the outcome and sex, age, ethnic origin, health authority, material deprivation, major mental illness, alcohol use problem, and chronic pain as independent variables (all measured at the index date; supplementary table B). Weights were truncated at 1st and 99th centiles. Models used a robust sandwich covariate matrix to account for intracluster correlation within each matched group. We used the cumulative sums of Martingale residuals and the Kolmogorov type supremum test to assess the non-proportional hazards assumption.

Sensitivity analyses
We conducted several sensitivity analyses, including a model with death as a competing risk, a model with inverse probability of censoring weights to account for artificial censoring at initiation of a long term episode (only applicable to individuals in the acute use and opioid naive categories), and a model using an alternate matched cohort limited to individuals with a history of chronic pain.

Patient and public involvement
This cohort study was developed without patient involvement owing to the retrospective, administrative, and de-identified nature of the data sources. The study was developed in response to concerns expressed by patients and the public regarding the contribution of prescription opioids to the illicit overdose crisis in British Columbia. These concerns were brought forward to members of the research team through peer based organisations of people with lived and living experience of substance use, the media, concerned friends and family members, providers, and provincial committees involved in the overdose response.

Results
Study population
The IDEAs PharmaNet database includes information for about 1.7 million individuals (1996-2015). Of 159,109 eligible individuals who had a first long term prescription opioid episode between 2000 and 2015 (fig 1), 14,975 had a first long term episode that was chronic (that is, lasting >90 episode days; with at least 90 days’ drug supply and at least 50% episode intensity). Almost all eligible people with a chronic episode (apart from 24 (0.2%) individuals) were matched (1:1:1:1) to an individual in the other opioid use categories (episodic, acute, opioid naive). The final matched cohort included 59,804 people (14,951 in each category).

Characteristics of study participants and success of IPTW weighting
Overall, 30,140 (50.4%) participants were male and the median age was 44 (interquartile range 35-55) years. The footnotes of table 1 show the breakdown of matched sociodemographic variables. With increasing length and intensity of prescription opioid use (that is, from opioid naive to chronic use), we observed an increasing proportion of people who were more materially deprived or had history of major mental illness, alcohol use problems, or chronic pain (table 1). Standardised mean differences were 0.1 or more for all covariates before weighting by IPTW (except for matched variables) and all were less than 0.1 after weighting (supplementary table C).

Prescription opioid episode characteristics
Half of the chronic opioid episodes were longer than two years, contained more than 1.5 years of drug supply, and had an average daily dose of higher than 32 morphine equivalents (supplementary table D). The corresponding characteristics were lower for episodic episodes (171 days, 22 days, and 22 morphine equivalents, respectively). Supplementary table D contains additional information on episode characteristics (eg, inferred indication, most common opioid formulation). Our previous analysis showed that most acute episodes (about 70%) contain ≤7 days’ supply of opioids.

Study follow-up and injection drug use initiation
The 59,804 individuals in the matched cohort were followed for a median of 5.8 years (interquartile range 3.0-9.4), and 1,149 participants initiated injection drug use (table 2). Risk of initiation was highest for the chronic use category, followed by the episodic use, acute use, and opioid naive categories (table 2, fig 2). In the chronic use category, risk of initiation was higher at younger ages (table 2, fig 2) and greater average daily dose (table 2, fig 2). Among individuals with chronic use who initiated injection drug use, the median time to identification of injection drug use through the administrative algorithm was 3.6 years (interquartile range 1.7-6.0).

Cox models
The magnitude of association between opioid use category (v opioid naive individuals) and injection drug use initiation increased with greater intensity and length of use (that is, chronic use had a greater association than episodic use, which was in turn greater than acute use; table 3). In the IPTW Cox model, risk of injection drug use initiation was 8.4 times (95% confidence interval 6.4 to 10.9) higher for people in the chronic opioid use category than for opioid naive individuals, 2.7 times (2.1 to 3.6) higher for people in the episodic use category, and 1.4 times (1.0 to 2.0) higher for people in the acute use category.

Sensitivity analyses
Sensitivity analyses were generally consistent with our primary results (supplementary table E). However, limiting the analysis to individuals with a history of chronic pain lowered the cumulative probabilities of injection drug use initiation but did not lower the hazard ratios (table 3).

Discussion

Principal findings

In this longitudinal analysis of roughly 60,000 matched individuals selected from a large administrative data source (all individuals tested for HIV or hepatitis C virus in the Canadian province of British Columbia), the rate of injection drug use initiation among individuals who received chronic prescription opioid treatment for non-cancer pain was infrequent overall (3.4% within five years), but 8-10 times higher than among opioid naive individuals. Notably, of the almost 15,000 individuals on chronic opioid treatment, half had used opioid treatments on most days for more than two years, and initiation of injection drug use was more frequent at higher doses and younger ages. We excluded people older than 65 years or with a history of substance use problems.
The literature, which has primarily focused on self-reported non-medical prescription opioid use (NMPOU) and heroin use,20 and also contributes to a relatively new field of research using administrative algorithms to identify injection drug use. Importantly, we were unable to determine the underlying reasons for initiation of injection drug use, or whether these initiations were causally related to opioid treatment.

Table 1 | Characteristics of study participants by prescription opioid use category, matched cohort (n=59804). Data are number (%) of participants

<table>
<thead>
<tr>
<th>Category</th>
<th>Chronic use (n=14951)</th>
<th>Episodic use (n=14951)</th>
<th>Acute use (n=14951)</th>
<th>Opioid naive (n=14951)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of participants</td>
<td>59804</td>
<td>14951</td>
<td>14951</td>
<td>14951</td>
</tr>
<tr>
<td>Total</td>
<td>350 131</td>
<td>357 87</td>
<td>29 70</td>
<td>69 9</td>
</tr>
<tr>
<td>Median (interquartile range)</td>
<td>5.8 (3.0-9.4)</td>
<td>5.8 (3.1-9.4)</td>
<td>7.3 (6.0-8.6)</td>
<td>6.7 (5.0-8.5)</td>
</tr>
<tr>
<td>No of incident IDU initiations</td>
<td>114 9</td>
<td>138 37</td>
<td>259 66</td>
<td>224 59</td>
</tr>
<tr>
<td>Rate of IDU initiation (per 1000 person years)</td>
<td>3.3</td>
<td>3.4</td>
<td>2.6</td>
<td>2.6</td>
</tr>
<tr>
<td>5 year cumulative probability of IDU initiation (%)</td>
<td>1.6</td>
<td>0.4</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Average daily dose (chronic use only, morphine equivalents)†</td>
<td>9.88</td>
<td>8.49</td>
<td>9.9</td>
<td>9.9</td>
</tr>
<tr>
<td>≥50</td>
<td>1083</td>
<td>6953</td>
<td>6.6 (3.8-10.0)</td>
<td>22.9 (15.3-30.3)</td>
</tr>
<tr>
<td>50-89</td>
<td>2574</td>
<td>15 259</td>
<td>6.0 (3.3-9.0)</td>
<td>13.9 (9.1-17.9)</td>
</tr>
<tr>
<td>90-199</td>
<td>1695</td>
<td>11 187</td>
<td>7.1 (4.0-10.0)</td>
<td>17.5 (13.6-21.6)</td>
</tr>
<tr>
<td>≥200</td>
<td>795</td>
<td>5589</td>
<td>7.9 (4.6-10.0)</td>
<td>22.4 (16.8-28.1)</td>
</tr>
<tr>
<td>Age (chronic use only, years)‡</td>
<td>1.08</td>
<td>0.69</td>
<td>0.6 (0.3-1.0)</td>
<td>1.29 (0.8-1.92)</td>
</tr>
<tr>
<td>≤25</td>
<td>2520</td>
<td>15 703</td>
<td>6.4 (3.7-10.0)</td>
<td>13.3 (9.4-17.3)</td>
</tr>
<tr>
<td>25-34</td>
<td>3382</td>
<td>23 540</td>
<td>7.8 (4.4-10.0)</td>
<td>8.2 (5.4-12.1)</td>
</tr>
<tr>
<td>35-44</td>
<td>784</td>
<td>44 338</td>
<td>5.4 (2.7-8.7)</td>
<td>4.5 (2.5-6.9)</td>
</tr>
</tbody>
</table>

*See methods for more details on opioid use categories.
†Average daily dose calculated as the cumulative prescribed morphine equivalents during episode divided by the number of episode days covered by drug supply. Age measured at initiation of chronic opioid use.

| Table 2 | Number of participants, follow-up time, and rate of injection drug use (IDU) initiation by prescription opioid use category

<table>
<thead>
<tr>
<th>Category</th>
<th>No of participants</th>
<th>Follow-up (person years)</th>
<th>Rate of IDU initiation (per 1000 person years)</th>
<th>5 year cumulative probability of IDU initiation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full matched cohort*</td>
<td>59804</td>
<td>350 131</td>
<td>5.8 (3.0-9.4)</td>
<td>114 9</td>
</tr>
<tr>
<td>Opioid naive</td>
<td>14951</td>
<td>357 87</td>
<td>5.8 (3.1-9.4)</td>
<td>138 37</td>
</tr>
<tr>
<td>Acute</td>
<td>14951</td>
<td>29 70</td>
<td>7.3 (6.0-8.6)</td>
<td>259 66</td>
</tr>
<tr>
<td>Long term (all)</td>
<td>29902</td>
<td>194 314</td>
<td>6.3 (3.4-10.0)</td>
<td>978</td>
</tr>
<tr>
<td>Epidemic</td>
<td>14951</td>
<td>93 780</td>
<td>6.5 (3.5-10.0)</td>
<td>248</td>
</tr>
<tr>
<td>Chronic</td>
<td>14951</td>
<td>90 534</td>
<td>6.2 (3.2-9.8)</td>
<td>730</td>
</tr>
</tbody>
</table>

Index date for measurement of variables was initiation date of long term use (for people in episodic and chronic use categories) or index date of the matched chronic use individual (for people in opioid naive and acute use categories). Individuals were matched on sex, birth year, and ethnic origin.

Data for sex, birth year, year of index date, approximate age (±1 year), and ethnic origin were similar across all categories (male (50.4%), female (49.6%); <1950s (17.4%), 1950-60s (53.0%), and 1970s (29.6%), 2000-04 (29.3%), 2005-09 (34.1%), and 2010-15 (36.6%); age <25 (7%), 25-34 (17%), 35-44 (23%), 45-54 (28%), and 55-65 (26%) years; and East Asian (2.2%), South Asian (5.6%), and other residents of British Columbia (92.2%), respectively.

All levels not shown for ease of presentation.

problem (except alcohol) at baseline. Aspects unique to our analysis include the use of a population based, dispensation data source to identify opioid treatment (all prescriptions dispensed from community pharmacies, regardless of payer) and the application of a highly specific administrative algorithm (validated in our data source) to identify initiation of injection drug use.18 30 Our analysis fills an important gap in the literature, which has primarily focused on self-reported non-medical prescription opioid use (NMPOU) and heroin use,20 and also contributes to a relatively new field of research using administrative algorithms to identify injection drug use. Importantly, we were unable to determine the underlying reasons for initiation of injection drug use, or whether these initiations were causally related to opioid treatment.
Fig 2 | Cumulative incidence of injection drug use initiation by prescription opioid use category, age at initiation of chronic episode (chronic use category only), and average daily dose of chronic episode (chronic use category only).

PO=prescription opioid; MEQ=morphine equivalents; IDU=injection drug use. See methods for more details on opioid use categories. Average daily dose calculated as the cumulative morphine equivalents dispensed during episode divided by number of episode days covered by drug supply.
Implications for clinicians and policy makers

Our findings could have implications for strategies to prevent the initiation of injection drug use (eg, more judicious opioid prescribing), but should not be used as a reason to support involuntary tapering or discontinuation of prescription opioid treatment. Abrupt discontinuation could lead to some individuals to access the increasingly dangerous illicit drug market, and could explain some of the initiations of injection drug use in our analysis. Inadequately managed pain and denial of pain drug treatments have been identified as risk factors for illicit drug use, particularly among people with history of substance use. The Canadian Pain Task Force has identified a need to foster shared decision making between providers and individuals living with chronic pain and “support opioid prescribing that balances the benefits and harms of these medications based on the needs of the individual.” Improved access to multidisciplinary approaches to treat pain is also needed. Regarding non-opioid interventions, evidence suggests that some non-invasive (eg, exercise therapy, multidisciplinary rehabilitation, cognitive behavioural therapy) and invasive (eg, nerve blocks) treatments can improve function and/or reduce pain for specific conditions.

The dose-response relation suggests that interventions aimed at preventing and treating prescription opioid dependence, appropriately tapering or discontinuing opioid use, and adequately treating pain (because dose might be a proxy for pain severity) could reduce the risk of injection drug use initiation. Guidelines generally recommend the avoidance of escalation to high doses, slow and voluntary tapering to the lowest effective dose (and potentially discontinuation) for people receiving high doses, and a multidisciplinary programme for individuals experiencing challenges in tapering. Best practices for treating opioid dependence include provision of opioid agonist treatment in conjunction with psychosocial interventions and supports. Harm reduction interventions (eg, sterile drug use equipment, safer injection sites, and use of prescription opioids as a pharmaceutical alternative to illicit drugs) could reduce the risk of downstream harms from illicit or injection drug use.

We also found male sex, younger age, higher material deprivation, and history of mental illness and alcohol use problems to be associated with the initiation of injection drug use. These populations might also benefit from enhanced efforts to prevent initiation of injection.

Comparison to other findings

Our large longitudinal analysis supports findings from several surveys and smaller longitudinal studies demonstrating an association between self-reported NMPOU and initiation of heroin use. While many of these studies enrolled specific populations and might not be widely generalisable, two large analyses of pooled data from a nationally representative survey in

---

**Table 3 | Association between prescription opioid use category and initiation of injection drug use in Cox models**

<table>
<thead>
<tr>
<th>Prescription opioid use category*</th>
<th>Full matched cohort (primary analysis; n=37,564)</th>
<th>Matched cohort of individuals with history of chronic pain (sensitivity analysis; n=33,564)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M</td>
<td>5 year cumulative probability of IDU initiation (%)</td>
</tr>
<tr>
<td>Opioid naive</td>
<td>14,951</td>
<td>0.4</td>
</tr>
<tr>
<td>Acute</td>
<td>14,951</td>
<td>0.7</td>
</tr>
<tr>
<td>Episodic</td>
<td>14,951</td>
<td>1.3</td>
</tr>
<tr>
<td>Chronic</td>
<td>14,951</td>
<td>4.0</td>
</tr>
</tbody>
</table>

HR=hazard ratio; aHR=adjusted hazard ratio; IPTW=inverse probability treatment weighting; IDU=injection drug use.

The multinomial logistic regression model used to calculate the generalised propensity scores for IPTW included the following variables: age, gender, education, income, employment status, marital status, history of chronic pain, and history of substance use. The multinomial logistic regression model used to generate propensity scores for patients living with chronic pain was adjusted for the same variables as the multinomial logistic regression model used to generate propensity scores for all patients. A matched cohort of individuals with history of chronic pain was created using a propensity score matching algorithm to account for imbalances in baseline characteristics. See methods for more details on opioid use categories.

---

**Note:**

1. BMJ: first published as 10.1136/bmj-2021-066965 on 18 November 2021. Downloaded from http://www.bmj.com on 22 November 2021 by guest. Protected by copyright.
the BMJ included in the multivariable Cox model. The Cox model used a robust sandwich covariate matrix to account for regression model used to calculate the generalised propensity scores for IPTW included all the variables Model also adjusted for health authority (no statistically significant associations). The multinomial logistic IPTW=inverse probability of treatment weighting.

Prescription opioid use category (v opioid naive)*

Table 4 | Characteristics associated with initiation of injection drug use in the multivariable IPTW Cox model, full matched cohort (n=59 804)

<table>
<thead>
<tr>
<th>Prescription opioid use category (v opioid naive)*</th>
<th>Adjusted hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute</td>
<td>1.4 (1.0 to 2.0)</td>
</tr>
<tr>
<td>Episodic</td>
<td>2.7 (2.1 to 3.6)</td>
</tr>
<tr>
<td>Chronic</td>
<td>8.4 (6.4 to 10.9)</td>
</tr>
<tr>
<td>Male sex (v female)</td>
<td>1.6 (1.4 to 1.8)</td>
</tr>
<tr>
<td>Age (v 55-65 years)</td>
<td>25-34 3.3 (2.6 to 4.2)</td>
</tr>
<tr>
<td></td>
<td>35-44 2.0 (1.6 to 2.6)</td>
</tr>
<tr>
<td></td>
<td>45-54 1.1 (0.9 to 1.5)</td>
</tr>
<tr>
<td>Ethnic origin (v other residents of British Columbia)</td>
<td>0.5 (0.3 to 0.7)</td>
</tr>
<tr>
<td>South Asian</td>
<td>0.4 (0.2 to 0.9)</td>
</tr>
<tr>
<td>Material deprivation (v 1 (least))</td>
<td>1.3 (1.0 to 1.6)</td>
</tr>
<tr>
<td>2</td>
<td>1.4 (1.1 to 1.8)</td>
</tr>
<tr>
<td>3</td>
<td>1.4 (1.1 to 1.8)</td>
</tr>
<tr>
<td>4</td>
<td>1.6 (1.3 to 2.0)</td>
</tr>
<tr>
<td>5 (most)</td>
<td>2.1 (1.2 to 3.7)</td>
</tr>
<tr>
<td>Missing†</td>
<td>0.8 (0.7 to 0.9)</td>
</tr>
<tr>
<td>Chronic pain</td>
<td>2.7 (2.2 to 3.3)</td>
</tr>
<tr>
<td>Major mental illness</td>
<td>1.6 (1.3 to 1.8)</td>
</tr>
</tbody>
</table>

IPTW=inverse probability of treatment weighting. Model also adjusted for health authority (no statistically significant associations). The multinomial logistic regression model used to calculate the generalised propensity scores for IPTW included all the variables included in the multivariable Cox model. The Cox model used a robust sandwich covariate matrix to account for intracluster correlation within each matched group.

*See methods on more details on opioid use categories.
†Missing material deprivation was retained in the model because it could be a proxy for homelessness.

Strengths and weaknesses of the study

Confounding could partly explain the association between prescription opioids and initiation of injection drug use, and could limit the extent to which firm conclusions can be drawn. We noted an increasing prevalence of potential risk factors for injection drug use across the gradient of increasing length and intensity of prescription opioid use (that is, from opioid naive to chronic use), including chronic pain, higher social or material deprivation, major mental illness, and alcohol use problems. To adjust for this potential source of bias, we matched on sociodemographic variables, used IPTW to balance further differences, and performed a sensitivity analysis limited to individuals with chronic pain (a key confounder by indication because individuals might transition to injection drug use to manage uncontrolled chronic pain, independent of their current or previous prescription opioid use). Among people with chronic opioid use in this sensitivity analysis, the cumulative probability of initiation decreased but the relative strength of association (hazard ratio) did not. Possible sources of residual confounding include the use of administrative databases to identify confounders (a source of misclassification bias), potential inclusion of individuals associating prescription opioids for non-pain purposes (eg, euphoric effects, dependence, off-label opioid agonist treatment), and the inability to adjust for severity of pain.

*Several strengths and weaknesses were related to the use of our administrative algorithm to identify injection drug use. Strengths include the high specificity of the algorithm, advantages compared to the use of self-report, and contribution to a relatively new field of research exploring the use of such algorithms (which is inherently challenged by the lack of diagnostic codes specific to injection drug use). Limitations include low sensitivity and low potential positive predictive value (owing to expected low prevalence of the outcome), validation of our algorithm via self-report (although self-report is generally considered the gold standard), inability to identify exact date of injection initiation, and delays between actual initiation and algorithm identification.

Our analysis had several other limitations, including challenges using pharmacy dispensation data to determine how drug treatments were actually taken and possible inclusion of people with undetected injection drug use at baseline (owing to the imperfect sensitivity of the algorithm). Furthermore, the dose-response analysis was based on the average daily dose across the full chronic episode and could include dispensations after initiation of injection drug use. We did not compare prescription opioids to alternative pain treatments, and this requires further research. Also, our analysis did not take into account the time varying nature of potential confounders; instead, covariates...
were measured as binary variables at study start. Although the study end date was 2015, our analysis captures an important period in British Columbia when prescription opioid use increased and could have contributed to the illicit opioid overdose epidemic that started in 2015-16 (by facilitating transitions to illicit or injection drug use). Finally, our study population was primarily limited to people tested for HIV or hepatitis C virus, potentially limiting generalisability of study findings. In particular, the absolute rates of injection drug use initiation could be higher in our study sample than the general population. However, HIV and hepatitis C virus testing is broadly offered to some populations in British Columbia (eg, pregnant people, baby boomers, sexually active individuals).

Conclusion

The rate of injection drug use initiation among individuals who received chronic prescription opioid treatment for non-cancer pain was infrequent overall (3.4% within five years), but 8-10 times higher than opioid naive individuals. Rate of initiation was more frequent with greater doses and at younger ages. Our findings could help inform strategies and policies to prevent further transitions to injection drug use and related harms secondary to such use, but should not be used as a reason to inappropriately taper or discontinue long term prescription opioid treatment.

**AUTHOR AFFILIATIONS**

1 British Columbia Centre for Disease Control, Vancouver, BC, Canada
2 School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
3 Centre for Health Evaluation and Outcome Sciences, St Paul’s Hospital Vancouver, BC, Canada
4 Pain Management Clinic, JPOCSC, Fraser Health Authority, Surrey, BC, Canada
5 Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
6 George and Fay Yee Centre for Healthcare Innovation, University of Manitoba, Winnipeg, MB, Canada
7 Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
8 Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada
9 ICES, Toronto, ON, Canada
10 Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO, USA
11 Department of Emergency Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
12 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
13 Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada

We thank the Provincial Health Services Authority, British Columbia Ministry of Health, and British Columbia Cancer staff for their assistance in data access, procurement, and management, and the residents of British Columbia, whose data are integrated in IDEAs and the British Columbia Hepatitis Testers Cohort. This work was carried out on the unceded traditional and ancestral territories of the Coast Salish people. All inferences, opinions, and conclusions drawn in this manuscript are those of the authors, and do not reflect the opinions or policies of the data stewards.

**Contributors:** JAB, RP, and NZ conceptualised the study. JAB, RP, and NZ (primary investigators) and TG, RCD, and RB (co-investigators) developed the grant to acquire funding. Project administration and supervision was provided by JAB, RP, NZ, and MA. JAB, RP, NZ, JW, and YA developed the study design. MEK, RB, and BZ contributed to the methodology. MA, SW, and AV were involved in data linkage and data management. MC and YA created the analytical dataset with assistance from SW and AV. JW and YA performed the formal analysis, and RP and JW wrote the original draft of the manuscript. JW and YA had full access to data in the study. JW accepts full responsibility for the work and the conduct of the study and is the guarantor. All authors reviewed the manuscript and contributed to interpretation of the data. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

**Funding:** This work was supported by British Columbia Centre for Disease Control and the Canadian Institutes of Health Research (PIT-156117, NH-C-142832). The funders were not involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

**Competing interests:** All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interests/ and declare: support from British Columbia Centre for Disease Control and the Canadian Institutes of Health Research for the submitted work; outside of the submitted work, MK has received research grant funding via his institution from Roche Molecular Systems, Siemens Healthcare Diagnostics, and Hologic; MEK has received consulting fees from Biogen; and RCD has performed research and consulted on the over-the-counter product 5fentanyl for the consumer division of Johnson & Johnson. RCD is executive director of the RADARS System, which performs post-marketing surveillance of prescription drugs. This information is primarily used for regulatory purposes. Subscribers to the RADARS System include the US Food and Drug Administration and some manufacturers of prescription analgesics or treatment for opioid addiction. These companies include Collegium, Purdue Pharma, and Indivior. All other authors report no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. All authors report no other relationships or activities that could appear to have influenced the submitted work.

**Ethical approval:** Data linkage to establish IDEAs and the British Columbia Hepatitis Testers Cohort was performed under the British Columbia Centre for Disease Control’s public health mandate. This study was approved by the University of British Columbia’s research ethics board (H14-01649).

**Data sharing:** The IDEAs cohort was made possible through a multi-agency collaboration, including the British Columbia Centre for Disease Control, British Columbia Centre for Disease Control’s Public Health Laboratory, British Columbia Cancer, and the British Columbia Ministry of Health. The integrated dataset involved the linkage of de-identified case, laboratory testing, and cancer data with health services administrative data. Authorised users have access to de-identified data based on roles and projects. Access to the de-identified data is not permitted outside of Canada. Use of the data is limited to the objectives described in the Information Sharing Plan. Individuals interested in becoming external collaborators can contact Naveed Janjua (naveed.janjua@bccdc.ca). The British Columbia Centre for Disease Control requires all internal and external researchers with access to analytical datasets to complete annual or more frequent privacy or confidentiality and information security and awareness training, sign confidentiality forms, and complete a concept note and data request.

The lead authors (JW, RP, NZ, JAB) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained.

**Dissemination to participants and related patient and public communities:** Results will be presented to peer based organisations of people with lived and living experience of substance use and provincial committees involved in the overdose response. We also plan to disseminate results more broadly through IDEAs and the British Columbia Hepatitis Testers Cohort Twitter page (@BCHeptCo) and website (https://bchtc.med.ubc.ca/).

**Provenance and peer review:** Not commissioned; externally peer reviewed.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

DOI: 10.1136/bmj-2021-066965 | BMJ 2021;375:e066965 | the bmj

BMJ: first published as 10.1136/bmj-2021-066965 on 18 November 2021. Downloaded from http://www.bmj.com on 22 November 2021 by guest. Protected by copyright.
Web appendix: Supplementary Appendix